# Bortezomib in Treating Patients With Waldenstrom's Macroglobulinemia

> **NCT00045695** · PHASE2 · COMPLETED · sponsor: **NCIC Clinical Trials Group** · enrollment: 27 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** bortezomib

## Key facts

- **NCT ID:** NCT00045695
- **Lead sponsor:** NCIC Clinical Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-08
- **Primary completion:** 2006-03
- **Final completion:** 2009-12
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2013-05-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00045695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00045695, "Bortezomib in Treating Patients With Waldenstrom's Macroglobulinemia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00045695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*